Why it Matters

This marks BradyPLUS’s first federal lobbying registration as the janitorial and foodservice distributor prepares for a massive merger with Imperial Dade. The combined entity would generate $10 billion in revenue, making it one of North America’s largest distributors. The timing coincides with heightened congressional scrutiny of corporate consolidation.

By the Numbers

  • External lobbying: Ballard Partners LLC handles all federal lobbying
  • Internal lobbying: None reported
  • Historical spending: No prior federal lobbying expenditures
  • Team: Two lobbyists – Brian David Ballard (founder/president) and Justin J. Sayfie
  • Registration date: January 27, 2025

Broader Context

Congress is actively pursuing antitrust reform through multiple bills. The Competition and Antitrust Law Enforcement Reform Act of 2025 aims to strengthen merger restrictions. The Preventing Algorithmic Collusion Act of 2025 targets pricing coordination practices. Recent FTC oversight hearings emphasized maintaining marketplace competition.

The Agenda

BradyPLUS registered to lobby on “Government competition policy.” The registration doesn’t specify particular legislation. However, the timing suggests focus on regulatory approval for their Imperial Dade merger. Ballard Partners previously lobbied on “ecommerce and competition policy” for Amazon.com Inc.

Competitive Landscape

Other major distributors are also lobbying on competition issues. Sysco Corporation and U.S. Foods focus on supply chain challenges. Albertsons lobbied on competition issues related to its proposed Kroger merger. Medical suppliers like Medline Industries and Cardinal Health emphasize supply chain resilience.

Between The Lines

Sen. Chris Murphy and Sen. Richard Blumenthal reintroduced antitrust reform legislation, warning large companies control “almost every aspect of our lives.” New Senate Judiciary Subcommittee leadership includes Sen. Mike Lee as chairman and Sen. Cory Booker as ranking member. Recent Senate hearings examined prescription drug supply chain competition, highlighting consolidation concerns.

The Bottom Line

BradyPLUS’s lobbying debut reflects the challenging regulatory environment facing large mergers. With experienced representation and strategic timing, the company positions itself for what could be a contentious review process. Success depends on convincing regulators the merger benefits consumers despite market concentration concerns.

Spot something wrong? Report an issue with this article